Agilent showcases comprehensive cancer portfolio solutions at AACR 2023

Agilent Technologies Inc., will introduce its new cell analysis, genomics, digital pathology, and companion diagnostics solutions at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, USA.

Cancer is the second most common cause of death in the US, and the incidence continues to increase, with over 1.9 million new cancer cases expected to be diagnosed in 2023. An estimated 41 out of 100 men and 39 out of 100 women will potentially develop cancer during their lifetime.

A highlight at AACR will be the full commercial launch of the new Agilent SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay, an NGS-based pan-cancer panel for somatic variant detection from solid tumors. This cancer CGP assay provides the ability to sequence DNA and RNA in parallel to detect key classes of somatic alterations.

Also announced is a strategic partnership between Agilent and PathAI to deliver AI-powered assay development solutions. Combining Agilent’s in vitro diagnostics workflow expertise with PathAI’s proprietary algorithm development platform will enable the integration of AI in CDx development, building intelligent solutions and assays with integrated AI algorithms from the outset. This builds on the announcement in March of an end-to-end solution for digital pathology that brings together products from Agilent, Visiopharm, Proscia^®, and Hamamatsu Photonics K.K.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>